Basic information
- Name:
Yohimban-16-carboxylicacid,17-hydroxy-,methyl ester, hydrochloride (1:1), (16a,17a)-
- Superlist Name:
- Yohimbine hydrochloride
- CAS No.:
65-19-0
- Molecular Structure:

- Formula:
- C21H26N2O3.ClH
- Molecular Weight:
- 354.44
- Synonyms:
- Yohimban-16-carboxylicacid, 17-hydroxy-, methyl ester, monohydrochloride, (16a,17a)- (9CI);Yohimban-16a-carboxylic acid, 17a-hydroxy-, methyl ester, monohydrochloride (8CI);Actibine;Antagonil;Yohimbe;Yohimbine monohydrochloride;Yohimex;Yohimbe Bark Extract;
- EINECS:
- 200-600-4
- Melting Point:
- 288-290 °C (dec.)(lit.)
- Boiling Point:
- 543 °C at 760 mmHg
- Flash Point:
- 282.2 °C
- Hazard Symbols:
T- Risk Codes:
- 23/24/25-33-23/24
- Safety Description:
- 22-36/37/39-45-24/25 Details
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
Consensus Reports
Specification
The CAS registry number of Yohimbine hydrochloride is 65-19-0. Its EINECS registry number is 200-600-4. The IUPAC name is methyl (16α,17α)-17-hydroxyyohimban-16-carboxylate hydrochloride (1:1). In addition, the molecular formula is C21H26N2O3.ClH and the molecular weight is 354.44. It is a kind of white to slightly yellow powder and belongs to the classes of Alkaloids; Biochemistry; Indole Alkaloids; Natural Plant Extract; Adrenoceptor; Adrenoceptors. What's more, it is a plant alkaloid with alpha-2-adrenergic blocking activity.
Physical properties about this chemical are: (1)ACD/LogP: 2.20; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -0.56; (4)ACD/LogD (pH 7.4): 1.05; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1.95; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 26.39; (9)#H bond acceptors: 5; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 3; (12)Polar Surface Area: 43.7 Å2; (13)Flash Point: 282.2 °C; (14)Enthalpy of Vaporization: 86.43 kJ/mol; (15)Boiling Point: 543 °C at 760 mmHg; (16)Vapour Pressure: 1.27E-12 mmHg at 25°C.
Uses of Yohimbine hydrochloride: it can be used for biochemical studies. And it is used as a mydriatic and in the treatment of erectile dysfunction. In addition, it can be used to get 2-hydroxy-1,2,3,4,4a,5,7,8,8a,13,13a,13b,14,14a-tetradecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester. This reaction will need reagent NaBH3CN and solvent trifluoroacetic acid. The yield is about 100%.
![Yohimbine hydrochloride can be used to get 2-hydroxy-1,2,3,4,4a,5,7,8,8a,13,13a,13b,14,14a-tetradecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester](/UserFilesUpload/Uses of Yohimbine hydrochloride.jpg)
When you are using this chemical, please be cautious about it as the following:
It has danger of cumulative effects. And it is toxic by inhalation, in contact with skin and if swallowed. During using it, wear suitable protective clothing and gloves and eye/face protection and avoid contact with skin and eyes. And in case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.). In addition, do not breathe dust.
You can still convert the following datas into molecular structure:
(1)SMILES: Cl.O=C(OC)[C@@H]5[C@H]4C[C@H]3c2nc1ccccc1c2CCN3C[C@@H]4CC[C@@H]5O
(2)InChI: InChI=1/C21H26N2O3.ClH/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24;/h2-5,12,15,17-19,22,24H,6-11H2,1H3;1H/t12-,15-,17-,18-,19+;/m0./s1
(3)InChIKey: PIPZGJSEDRMUAW-VJDCAHTMBF
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LDLo | subcutaneous | 20mg/kg (20mg/kg) | PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE AUTONOMIC NERVOUS SYSTEM: OTHER (DIRECT) PARASYMPATHOMIMETIC BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | "Zur Pharmakologie der Yohimbealkaloide, Dissertation," Langer, J., Institute fuer Pharmakologie und Experimentelle Therapie der Universitat Breslau, Poland, 1932Vol. -, Pg. -, 1932. |
| frog | LD50 | parenteral | 26mg/kg (26mg/kg) | Bulletin des Sciences Pharmacologiques. Vol. 47, Pg. 33, 1940. | |
| frog | LD50 | subcutaneous | 34mg/kg (34mg/kg) | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 137, Pg. 305, 1943. | |
| guinea pig | LD50 | intraperitoneal | 42mg/kg (42mg/kg) | Bulletin des Sciences Pharmacologiques. Vol. 47, Pg. 33, 1940. | |
| man | TDLo | oral | 133ug/kg (0.133mg/kg) | BEHAVIORAL: EUPHORIA | American Journal of Psychiatry. Vol. 141, Pg. 1267, 1984. |
| mouse | LD50 | intraperitoneal | 45mg/kg (45mg/kg) | United States Patent Document. Vol. #4179510, | |
| mouse | LD50 | oral | 40mg/kg (40mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Journal of Pharmaceutical Sciences. Vol. 51, Pg. 345, 1962. |
| mouse | LD50 | subcutaneous | 43900ug/kg (43.9mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | British Journal of Pharmacology and Chemotherapy. Vol. 21, Pg. 51, 1963. |
| mouse | LDLo | intravenous | 15mg/kg (15mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 50, Pg. 241, 1935. | |
| rabbit | LDLo | intravenous | 5mg/kg (5mg/kg) | "Zur Pharmakologie der Yohimbealkaloide, Dissertation," Langer, J., Institute fuer Pharmakologie und Experimentelle Therapie der Universitat Breslau, Poland, 1932Vol. -, Pg. -, 1932. | |
| rat | LD50 | intraperitoneal | 55mg/kg (55mg/kg) | BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS AUTONOMIC NERVOUS SYSTEM: CENTRAL SYMPATHOLYTIC | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 110, Pg. 20, 1957. |
| women | TDLo | oral | 400ug/kg (0.4mg/kg) | BEHAVIORAL: EUPHORIA BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | American Journal of Psychiatry. Vol. 141, Pg. 1267, 1984. |

